Advertisement
Advertisement

BCRX

BCRX logo

BioCryst Pharmaceuticals Inc

9.53
USD
Sponsored
-0.21
-2.16%
Jul 29, 15:59 UTC -4
Closed
exchange

After-Market

9.47

-0.06
-0.66%

BCRX Earnings Reports

Positive Surprise Ratio

BCRX beat 22 of 42 last estimates.

52%

Next Report

Next Week
Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$186.26M
/
$0.12
Implied change from Q1 26 (Revenue/ EPS)
+19.08%
/
-233.33%
Implied change from Q2 25 (Revenue/ EPS)
+14.02%
/
+200.00%

BioCryst Pharmaceuticals Inc earnings per share and revenue

On May 06, 2026, BCRX reported earnings of -0.09 USD per share (EPS) for Q1 26, missing the estimate of 0.04 USD, resulting in a -281.82% surprise. Revenue reached 156.41 million, compared to an expected 154.15 million, with a 1.47% difference. The market reacted with a -2.21% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of 0.12 USD, with revenue projected to reach 186.26 million USD, implying an decrease of -233.33% EPS, and increase of 19.08% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Corcept Therapeutics Inc.
Report Date
Jul 29, 2026 For Q2 26
Estimate
$0.00
Actual
$0.36
Surprise
+6,958.82%
logo
Summit Therapeutics Inc. Common Stock
Report Date
Jul 23, 2026 For Q2 26
Estimate
-$0.28
Actual
-$0.28
Surprise
+1.72%
logo
Ionis Pharmaceuticals, Inc. Common Stock
Report Date
Jul 29, 2026 For Q2 26
Estimate
-$1.08
Actual
-$0.43
Surprise
+60.53%
logo
Champions Oncology, Inc.
Report Date
Jul 27, 2026 For Q4 26
Estimate
-$0.05
Actual
-$0.05
Surprise
+1.96%
FAQ
For Q1 2026, BioCryst Pharmaceuticals Inc reported EPS of -$0.09, missing estimates by -281.82%, and revenue of $156.41M, 1.47% above expectations.
The stock price moved down -2.21%, changed from $9.03 before the earnings release to $8.83 the day after.
The next earning report is scheduled for Aug 05, 2026.
Based on 6 analysts, BioCryst Pharmaceuticals Inc is expected to report EPS of $0.12 and revenue of $186.26M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement